Abstract
Pancreatic cancer remains one of the most lethal malignancies with little improvement in survival over the past several decades in spite of advances in imaging, risk factor identification, surgical technique and chemotherapy. This disappointing outcome is mainly due to failures to make an early diagnosis. In fact, the majority of the patients present with inoperable advanced stages of the disease. Though some of the new tumor markers are promising, we are still in search of the one that has a high sensitivity and accuracy, yet is inexpensive and easy to obtain. The paradigm of management has shifted from up-front surgery followed by adjuvant chemotherapy to neoadjuvant chemoradiation followed by surgery, especially for borderline resectable cancers and even for some resectable cancers. In this article, we will critically assess the limitations of tumor markers and review the advancements in endoscopic techniques in the management of pancreatic cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1027-1039 |
Number of pages | 13 |
Journal | Expert Review of Gastroenterology and Hepatology |
Volume | 10 |
Issue number | 9 |
DOIs | |
State | Published - Sep 1 2016 |
Keywords
- Pancreatic cancer
- endoscopic ultrasound-guided FNA
- neoadjuvant chemoradiation
- radiofrequency ablation
- self-expanding metal stent
- tumor markers
ASJC Scopus subject areas
- Hepatology
- Gastroenterology